{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:13:22Z","timestamp":1793157202296,"version":"4.5.0"},"reference-count":19,"publisher":"Centers for Disease Control MMWR Office","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7501a2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:47:46Z","timestamp":1767883666000},"page":"7-14","source":"Crossref","is-referenced-by-count":8,"title":["Use of the GSK MenACWY-CRM\/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged \u226510 Years: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2025"],"prefix":"10.15585","volume":"75","author":[{"given":"Avnika B.","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Loehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R1","unstructured":"Rubis A, Schillie S. Meningococcal disease [Chapter 8]. In: Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/surv-manual\/php\/table-of-contents\/chapter-8-meningococcal-disease.html"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020.","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","article-title":"Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"73","author":"Collins","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R4","unstructured":"Food and Drug Administration. Biologics license application approval [Letter]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2025. https:\/\/www.fda.gov\/media\/185482\/download?attachment"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R5","unstructured":"CDC; Advisory Committee on Immunization Practices. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK\u2019s pentavalent meningococcal vaccine (MenACWY-CRM\/MenB-4C). http:\/\/www.cdc.gov\/acip\/grade\/mening-menacwy-crm-menb-4c.html"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","article-title":"New dosing interval and schedule for the Bexsero MenB-4C vaccine: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, October 2024.","volume":"73","author":"Schillie","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/21645515.2015.1029686","article-title":"Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.","volume":"11","author":"Saez-Llorens","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R8","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial.","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R9","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.vaccine.2018.07.016","article-title":"Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - results from a randomized, controlled, observer-blind phase II study.","volume":"36","author":"Welsch","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R10","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1080\/21645515.2021.1968214","article-title":"Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.","volume":"17","author":"Vesikari","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R11","doi-asserted-by":"publisher","first-page":"e0055321","DOI":"10.1128\/mSphere.00553-21","article-title":"Immunogenicity and safety of investigational MenABCWY vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: a phase 2 randomized study of adolescents and young adults.","volume":"6","author":"Beran","year":"2021","journal-title":"mSphere"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R12","unstructured":"GSK. Immunogenicity and safety study of GSK's MenABCWY vaccine in healthy adolescents and adults previously primed with MenACWY vaccine. Bethesda, MD: GSK; 2024. Report no. NCT04707391. https:\/\/clinicaltrials.gov\/study\/NCT04707391"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R13","unstructured":"GSK. Effectiveness of GlaxoSmithKline Biologicals S.A's meningococcal group B and combined ABCWY vaccines in healthy adolescents and young adults. Bethesda, MD: GSK; 2024. Report no. NCT04502693. https:\/\/clinicaltrials.gov\/study\/NCT04502693"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. tThe role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14760584.2022.2064850","article-title":"Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage.","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R16","unstructured":"Schillie S. CDC; Advisory Committee on Immunization Practices. GSK pentavalent (MenABCWY) vaccine: review of updated EtR and work group considerations [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting; Atlanta, GA: April 16, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/02-Schillie-mening-508.pdf"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R17","doi-asserted-by":"publisher","first-page":"127332","DOI":"10.1016\/j.vaccine.2025.127332","article-title":"Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States.","volume":"61","author":"Dong","year":"2025","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R18","unstructured":"Dong X, Leidner A, Schillie S, McNamara L. CDC; Advisory Committee on Immunization Practices. Economic analyses of GSK MenABCWY vaccinations among adolescents in the United States [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting; Atlanta, GA; October 24, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/02-Mening-Dong-508.pdf"},{"key":"key-10.15585\/mmwr.mm7501a2-202601080958-R19","unstructured":"CDC. Vaccine administration [Chapter 6]. In: Epidemiology and prevention of vaccine-preventable diseases [the Pink Book]. Atlanta, GA: US Department of Health and Human Services, CDC; 2025. https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-6-vaccine-administration.html"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:58:52Z","timestamp":1767884332000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/75\/wr\/mm7501a2.htm?s_cid=mm7501a2_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7501a2","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,8]]},"published":{"date-parts":[[2026,1,8]]}}}